Polyclonal T-lymphocyte antigens (T-cell antigens)

Polyclonal T-lymphocyte antigens represent a broad array of surface proteins expressed on T-cells and thymocytes, including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD40, and HLA class I and II molecules. These antigens are critical for T-cell maturation, activation, and the execution of the adaptive immune response. In the context of clinical medicine, they serve as the collective target for antithymocyte globulins (ATG), which are polyclonal antibodies derived from horses or rabbits immunized with human thymocytes. By binding to this diverse set of receptors and signaling molecules, these therapeutic agents induce rapid and profound lymphopenia. This broad-spectrum immunosuppression is primarily utilized to prevent and treat acute organ rejection in transplant recipients and to manage severe aplastic anemia by suppressing the T-cell-mediated destruction of bone marrow stem cells. Because the target is a heterogeneous group of proteins rather than a single molecule, the resulting effect is a comprehensive modulation of the T-cell compartment, though this lack of specificity also contributes to significant side effects such as cytokine release and increased susceptibility to infections.

Other names

Thymocyte antigensT-lymphocyte surface antigensT-cell surface proteinsAntithymocyte globulin targets

Drugs targeting these antigens work through the depletion of circulating T-lymphocytes via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and opsonization followed by phagocytosis in the reticuloendothelial system. They also induce apoptosis of T-cells and modulate surface molecules involved in T-cell activation and trafficking.